SCHEMBL23488359

SCHEMBL23488359

COc1cc(OCc2cccc(CNC(=O)CCCCCCC(=O)OC(C)(C)C)c2)c(Cl)cc1C(=O)O[C@H]1[C@@H](OC)O[C@H](CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.38

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 2/20 0.38
LGALS9 O00182 1/20 0.38
LGALS1 P09382 1/20 0.38
LGALS7; LGALS7B P47929 1/20 0.38
LGALS8 O00214 2/20 0.36
HTR4 Q13639 1/20 0.34
TRPV1 Q8NER1 7/20 0.33
EPHX2 P34913 2/20 0.33
LGALS4 P56470 1/20 0.33
HDAC8 Q9BY41 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488493 0.98 LGALS3 (0.38) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488580 0.96 LGALS3 (0.36) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488335 0.95 LGALS3 (0.39) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488585 0.92 LGALS3 (0.40) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488768 0.91 HDAC8 (0.38) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488331 0.90 LGALS8 (0.43) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488343 0.90 LGALS3 (0.41) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488669 0.90 LGALS3 (0.41) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488243 0.89 CA2 (0.36) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488194 0.89 CA2 (0.36) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 LGALS3 156/4885LGALS9 106/4885LGALS1 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.